J Clin Psychopharmacol 2021 May 6. Epub 2021 May 6.
From the Department of Psychiatry, Zucker Hillside Hospital, Glen Oaks Feinstein Institutes for Medical Research, Institute for Behavioral Science, Manhasset Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Hempstead Icahn School of Medicine at Mount Sinai, New York, NY Brigham and Women's Hospital, Mood and Psychosis Research Program, Boston Department of Psychiatry, Harvard Medical School, Cambridge, MA.
Background: Adults with bipolar disorder (BD) often experience neurocognitive impairment that negatively impacts functioning and quality of life. Previous trials have found that dopamine agonist agents improve cognition in healthy volunteers and that adults with BD who have stable mood and mild cognitive deficits may also benefit. We hypothesized that pramipexole, a dopamine agonist, would improve neurocognitive function in patients with BD. Read More